February 22, 2013
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
FDA approves new pediatric dosing for Suprax
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA approved this week a new drug application for 500 mg/5 mL oral suspension for cefixime, according to the FDA.
Cefixime (Suprax, Lupin Pharmaceuticals) oral suspension 500 mg/5 mL should be available in the near future, according to a company press release.
Cefixime, a cephalosporin, is currently available as 100 mg/5 mL and 200 mg/5 mL suspensions; 400 mg tablets and chewable tablets in 100 mg and 200 mg.
The drug is indicated for the treatment of otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections, uncomplicated gonorrhea (cervical/urethral) and pharyngitis/tonsillitis in children aged 6 months and older.
Visit the FDA site for more information.